An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Adocia (Euronext: ADOC) announces its participation in several investor events in January 2023, focusing on diabetes and metabolic disease treatments. Events include the ODDO BHF Forum (Jan 9-10, virtual) and the JPM 2023 Healthcare Meeting (Jan 9-12, San Francisco). Additionally, Olivier Soula, Deputy CEO, will present at the Biotech Showcase (Jan 9-11, San Francisco) on Jan 10, discussing innovations in diabetes and the company's clinical programs. Adocia specializes in therapeutic solutions for metabolic diseases.
Positive
None.
Negative
None.
LYON, France--(BUSINESS WIRE)--
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its participation to the following investors events:
ODDO BHF Forum(January 9 and 10, 2023, virtual)
During these professional meetings with the financial community, through "one-to-one" or "one-to-few" formats, Adocia's management will review Adocia's news and outlook for 2023.
JPM 2023 - 41st Annual Healthcare Meeting (January 9 - 12, 2023, in San Francisco)
Adocia will attend at the JP Morgan 2023 and will meet with investors and leaders in healthcare.
Biotech Showcase (January 9 - 11, 2023, in San Francisco)
Olivier Soula, Adocia Deputy CEO, will present “Innovation in diabetes and "diabesity", from protein delivery to cell therapy”, at the Biotech Showcase on January 10th.
During this conference dedicated to investors, Olivier Soula will review the progress of Adocia's flagship clinical programs in diabetes (BioChaperone® Lispro and M1Pram) and present the latest results of the AdoShell® technology in cell therapy.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms:
1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families.
Based in Lyon, the company has about 100 employees. Adocia is listed on the regulated market of EuronextTMParis (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com, in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
Ulysse Communication
Adocia Press and Investors Relations
Pierre-Louis Germain Margaux Puech Pays d’Alissac
Bruno Arabian adocia@ulysse-communication.com
+ 33 (0)6 64 79 97 51
Source: ADOCIA
FAQ
What investor events is Adocia participating in January 2023?
Adocia will participate in the ODDO BHF Forum (January 9-10, virtual), JPM 2023 Healthcare Meeting (January 9-12, San Francisco), and Biotech Showcase (January 9-11, San Francisco).
Who will present at the Biotech Showcase for Adocia?
Olivier Soula, Deputy CEO of Adocia, will present on January 10, discussing diabetes innovations.
What is the focus of Adocia's upcoming presentations?
Adocia's presentations will focus on their clinical programs for diabetes, specifically BioChaperone Lispro and M1Pram, as well as AdoShell technology.
What is the significance of the events for Adocia?
These events provide Adocia an opportunity to engage with investors and showcase advancements in their diabetes treatment technologies.
What is Adocia's stock symbol?
Adocia is listed under the stock symbol ADOC on Euronext Paris.
